Overview

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

Status:
Active, not recruiting

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

This study aims to evaluate whether the addition of lenalidomide to rituximab-maintenance improves progression free survival (PFS) compared to standard rituximab maintenance after induction treatment consisting of R-CHOP + R-HAD vs R-CHOP alone in older patients (≥ 60 year old) with mantle cell lymphoma. The treatments consist of two phases: induction treatment (3 R-CHOP21 + 3 cycles of R-HAD28 alternating) vs 8 cycles of R-CHOP21) followed by maintenance treatment (13 cycles of rituximab + 26 cycles of lenalidomide vs 13 cycles of rituximab).

Phase:

Phase 3

Details

Lead Sponsor:

The Lymphoma Academic Research Organisation

Treatments:

Cyclophosphamide
Doxorubicin
Lenalidomide
Prednisone
Rituximab
Thalidomide
Vincristine